The 2026 NCCN Bladder Cancer Guidelines incorporate the IBCG five-factor model, introducing standardized risk stratification for intermediate-risk NMIBC. For decades, heterogeneity in ...

Categorizing patients with cancer by their disease stage can be an important tool when conducting administrative claims-based studies. As claims databases frequently do not capture this information, ...

The collaborative clinical study will evaluate ADSTILADRIN® (nadofaragene firadenovec-vncg) in combination with the investigational drug Ruvidar ® (TLD-1433) in patients with Bacillus ...

Tackling a common childhood virus could open the door to preventing bladder cancer, according to new research funded by Kidney Research UK and York Against Cancer. The study, published in Science ...

Alignment with U.S. FDA on design of Phase 2/3 registrational trial, to be initiated in 1Q 2024 Innovative study design allows for potential accelerated approval in untreated (first-line) and ...

Bladder cancer is the tenth most common type of cancer worldwide and is often linked to exposure to harmful chemicals, such as those found in tobacco smoke. A new study shows that the bacteria in our ...